Lexeo Therapeutics, Inc. Common Stock (LXEO) Research
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Market snapshot
- Symbol
- LXEO
- Price
- $4.93
- Day change
- -1.00%
- Market cap
- $387.1M
- P/E ratio
- -4.57x
- 52-week range
- 3.6-10.99
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $10.00
Recent news
- Why Is Lexeo Therapeutics Stock Gaining Monday?
Lexeo Therapeutics Inc. (NASDAQ:LXEO) stock rose Monday as the company announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006.
Peer companies
Recent insider activity
- Otero Jose Manuel — S-Sale (1302 shares) on 2026-05-18
- Townsend Richard Nolan — S-Sale (3342 shares) on 2026-05-18
- Sepp-Lorenzino Laura — A-Award (50000 shares) on 2026-04-28
- Sepp-Lorenzino Laura — trade (0 shares) on 2026-04-28
- Townsend Richard Nolan — S-Sale (55000 shares) on 2026-04-06
Open Lexeo Therapeutics, Inc. Common Stock (LXEO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.